{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:59:16Z","timestamp":1790690356172,"version":"4.1.0"},"reference-count":50,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000},"content-version":"unspecified","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology of Japan","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Glob Health"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      The rising burden of drug resistance is a major challenge to the global fight against malaria. We estimated national\n                      <jats:italic>Plasmodium falciparum<\/jats:italic>\n                      resistance to sulfadoxine-pyrimethamine (SP) across Africa, from 2000 to 2020.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We assembled molecular, clinical and endemicity data covering malaria-endemic African countries up to December 2018. Subsequently, we reconstructed georeferenced patient data, using pfdhps540E and pfdhps581G to measure mid-level and high-level SP resistance. Gaussian process regression was applied to model spatiotemporal standardised prevalence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In eastern Africa, mid-level SP resistance increased by 64.0% (95% uncertainty interval, 30.7%\u201369.8%) in Tanzania, 55.4% (31.3%\u201365.2%) in Sudan, 45.7% (16.8%\u201354.3%) in Mozambique, 29.7% (10.0%\u201345.2%) in Kenya and 8.7% (1.4%\u201336.8%) in Malawi from 2000 to 2010. This was followed by a steady decline of 76.0% (39.6%\u201392.6%) in Sudan, 65.7% (25.5%\u201385.6%) in Kenya and 17.4% (2.6%\u201337.5%) in Tanzania from 2010 to 2020. In central Africa, the levels increased by 28.9% (7.2%\u201362.5%) in Equatorial Guinea and 85.3% (54.0%\u201395.9%) in the Congo from 2000 to 2020, while in the other countries remained largely unchanged. In western Africa, the levels have remained low from 2000 to 2020, except for Nigeria, with a reduction of 14.4% (0.7%\u201367.5%) and Mali, with an increase of 7.0% (0.8%\u201325.6%). High-level SP resistance increased by 5.5% (1.0%\u201320.0%) in Malawi, 4.7% (0.5%\u201325.4%) in Kenya and 2.0% (0.1%\u201339.2%) in Tanzania, from 2000 to 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Under the WHO protocols, SP is no longer effective for intermittent preventive treatment in pregnancy and infancy in most of eastern Africa and parts of central Africa. Strengthening health systems capacity to monitor drug resistance at subnational levels across the endemicity spectrum is critical to achieve the global target to end the epidemic.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgh-2020-003217","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T18:49:10Z","timestamp":1605811750000},"page":"e003217","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":88,"title":["<i>Plasmodium falciparum<\/i>\n                    resistance to sulfadoxine-pyrimethamine in Africa: a systematic analysis of national trends"],"prefix":"10.1136","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1460-9522","authenticated-orcid":false,"given":"Floriano","family":"Amimo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Magit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jahit","family":"Sacarlal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hashizume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Shibuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,11,19]]},"reference":[{"key":"2020111913100926000_5.11.e003217.1","unstructured":"World Health Organization . World malaria report 2019. World Health Organization, 2019."},{"key":"2020111913100926000_5.11.e003217.2"},{"key":"2020111913100926000_5.11.e003217.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606701"},{"key":"2020111913100926000_5.11.e003217.4","doi-asserted-by":"publisher","DOI":"10.1038\/nature15535"},{"key":"2020111913100926000_5.11.e003217.5","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-09991-4","article-title":"The economics of malaria control in an age of declining aid","volume":"10","author":"Maskin","year":"2019","journal-title":"Nat Commun"},{"key":"2020111913100926000_5.11.e003217.6","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.13-0129"},{"key":"2020111913100926000_5.11.e003217.7","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-017-1817-9"},{"key":"2020111913100926000_5.11.e003217.8","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-016-1339-x","article-title":"High efficacy of artemether-lumefantrine and declining efficacy of artesunate + sulfadoxine-pyrimethamine against Plasmodium falciparum in Sudan (2010-2015): evidence from in vivo and molecular marker studies","volume":"15","author":"Adeel","year":"2016","journal-title":"Malar J"},{"key":"2020111913100926000_5.11.e003217.9","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/tmi.12458","article-title":"Treatment of uncomplicated malaria with artesunate plus sulfadoxine-pyrimethamine is failing in Somalia: evidence from therapeutic efficacy studies and Pfdhfr and Pfdhps mutant alleles","volume":"20","author":"Warsame","year":"2015","journal-title":"Trop Med Int Health"},{"key":"2020111913100926000_5.11.e003217.10","doi-asserted-by":"publisher","DOI":"10.1179\/136485905X36299"},{"key":"2020111913100926000_5.11.e003217.11","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-4-14"},{"key":"2020111913100926000_5.11.e003217.12","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.actatropica.2008.10.009","article-title":"Efficacy of monotherapies and artesunate-based combination therapies in children with uncomplicated malaria in Somalia","volume":"109","author":"Warsame","year":"2009","journal-title":"Acta Trop"},{"key":"2020111913100926000_5.11.e003217.13","unstructured":"World Health Organization . WHO policy recommendation on intermittent preventive treatment during infancy with sulphadoxine-pyrimethamine (SP-IPTi) for Plasmodium falciparum malaria control in Africa. World Health Organization, 2010."},{"key":"2020111913100926000_5.11.e003217.14","unstructured":"World Health Organization . WHO evidence review group on intermittent preventive treatment (IPT) of malaria in pregnancy. World Health Organization, 2013."},{"key":"2020111913100926000_5.11.e003217.15","unstructured":"World Health Organization . Intermittent preventive treatment in infants (IPTi). World Health Organization, 2017."},{"key":"2020111913100926000_5.11.e003217.16","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-12-249"},{"key":"2020111913100926000_5.11.e003217.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0035-9203(01)90250-0"},{"key":"2020111913100926000_5.11.e003217.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.pt.2010.05.001"},{"key":"2020111913100926000_5.11.e003217.19","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.35832"},{"key":"2020111913100926000_5.11.e003217.20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0901415106"},{"key":"2020111913100926000_5.11.e003217.21","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30732-1"},{"key":"2020111913100926000_5.11.e003217.22","unstructured":"Global Burden of Disease Collaborative Network . Global burden of disease study 2017 (GBD 2017) socio-demographic index (SDI) 1950\u20132017. Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2018."},{"key":"2020111913100926000_5.11.e003217.23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-024313"},{"key":"2020111913100926000_5.11.e003217.24","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/S0140-6736(16)30388-9","article-title":"Guidelines for accurate and transparent health estimates reporting: the GATHER statement","volume":"388","author":"Stevens","year":"2016","journal-title":"The Lancet"},{"key":"2020111913100926000_5.11.e003217.25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001488"},{"key":"2020111913100926000_5.11.e003217.26","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0140-6736(01)06201-8","article-title":"Plasmodium falciparum crossresistance between trimethoprim and pyrimethamine","volume":"358","author":"Iyer","year":"2001","journal-title":"The Lancet"},{"key":"2020111913100926000_5.11.e003217.27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007223","article-title":"The prevalence and antifolate drug resistance profiles of Plasmodium falciparum in study participants randomized to discontinue or continue cotrimoxazole prophylaxis","volume":"13","author":"Juma","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"2020111913100926000_5.11.e003217.28","doi-asserted-by":"crossref","unstructured":"Rasmussen C . Gaussian processes for machine learning. MA, USA: MIT Press Cambridge, 2006.","DOI":"10.7551\/mitpress\/3206.001.0001"},{"key":"2020111913100926000_5.11.e003217.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.pt.2013.08.002"},{"key":"2020111913100926000_5.11.e003217.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-06708-9"},{"key":"2020111913100926000_5.11.e003217.31","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000169.pub2","article-title":"Drugs for preventing malaria in pregnant women","volume":"4","author":"Garner","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"2020111913100926000_5.11.e003217.32","unstructured":"World Health Organization . Intermittent preventive treatment in pregnancy (IPTp). World Health Organization, 2019."},{"key":"2020111913100926000_5.11.e003217.33","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1111\/tmi.12595","article-title":"Influence of malaria transmission intensity and the 581G mutation on the efficacy of intermittent preventive treatment in pregnancy: systematic review and meta-analysis","volume":"20","author":"Chico","year":"2015","journal-title":"Trop Med Int Health"},{"key":"2020111913100926000_5.11.e003217.34","unstructured":"World Health Organization . Implementing malaria in pregnancy programs in the context of World Health Organization recommendations on antenatal care for a positive pregnancy experience. World Health Organization, 2018."},{"key":"2020111913100926000_5.11.e003217.35","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-015-2109-3","article-title":"Household antimicrobial self-medication: a systematic review and meta-analysis of the burden, risk factors and outcomes in developing countries","volume":"15","author":"Ocan","year":"2015","journal-title":"BMC Public Health"},{"key":"2020111913100926000_5.11.e003217.36","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-10-238"},{"key":"2020111913100926000_5.11.e003217.37","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ881"},{"key":"2020111913100926000_5.11.e003217.38","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-0909-7"},{"key":"2020111913100926000_5.11.e003217.39","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir376"},{"key":"2020111913100926000_5.11.e003217.40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056183"},{"key":"2020111913100926000_5.11.e003217.41","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.216231"},{"key":"2020111913100926000_5.11.e003217.42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3156.2011.02765.x"},{"key":"2020111913100926000_5.11.e003217.43","doi-asserted-by":"crossref","DOI":"10.3201\/eid1909.130133","article-title":"Plasmodium falciparum mutant haplotype infection during pregnancy associated with reduced birthweight, Tanzania","volume":"19","author":"Minja","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"2020111913100926000_5.11.e003217.44","unstructured":"World Health Organization . Seasonal malaria chemoprevention with sulfadoxine\u2013pyrimethamine plus amodiaquine in children: a field guide. World Health Organization, 2013."},{"key":"2020111913100926000_5.11.e003217.45","unstructured":"World Health Organization . WHO policy recommendation: seasonal malaria chemoprevention (SMC) for Plasmodium falciparum malaria control in highly seasonal transmission areas of the Sahel sub-region in Africa. World Health Organization, 2012."},{"key":"2020111913100926000_5.11.e003217.46","article-title":"Intermittent preventive treatment for malaria in children living in areas with seasonal transmission","volume":"367","author":"Meremikwu","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2020111913100926000_5.11.e003217.47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016976"},{"key":"2020111913100926000_5.11.e003217.48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12936-020-03175-y","article-title":"Impact of seasonal malaria chemoprevention on hospital admissions and mortality in children under 5 years of age in Ouelessebougou, Mali","volume":"19","author":"Issiaka","year":"2020","journal-title":"Malar J"},{"key":"2020111913100926000_5.11.e003217.49","doi-asserted-by":"crossref","DOI":"10.1186\/s12936-017-1974-x","article-title":"Measuring the impact of seasonal malaria chemoprevention as part of routine malaria control in Kita, Mali","volume":"16","author":"Diawara","year":"2017","journal-title":"Malar J"},{"key":"2020111913100926000_5.11.e003217.50","unstructured":"President\u2019s Malaria Initiative . Kenya malaria operational plan FY 2019. President\u2019s Malaria Initiative, 2019."}],"container-title":["BMJ Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgh-2020-003217","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T18:49:33Z","timestamp":1605811773000},"score":1,"resource":{"primary":{"URL":"https:\/\/gh.bmj.com\/lookup\/doi\/10.1136\/bmjgh-2020-003217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":50,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11,19]]},"published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1136\/bmjgh-2020-003217"],"URL":"https:\/\/doi.org\/10.1136\/bmjgh-2020-003217","relation":{},"ISSN":["2059-7908"],"issn-type":[{"value":"2059-7908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}